EQS-News: ABIVAX / Key word: Study results
Abivax reports two-year efficacy and safety data of obefazimod phase 2b maintenance trial in ulcerative colitis
17.04.2023 / 18:00. | April 17, 2023
Abivax will be presenting a poster on blood and rectal tissue data from ulcerative colitis (UC) patients, confirming the novel mechanism of action of obefazimod based on the upregulation of a single microRNA
The scientific article in the peer-reviewed journal Clinical and Translational Gastroenterology describes obefazimod's capacity to selectively up-regulate a single microRNA, miR-124, leading to decreases
First patient enrolled into the global phase 3 program with obefazimod ("ABTECT-Program") for the treatment of moderate to severe ulcerative colitis (UC) in the US1,200 UC patients across 36 countries
Abivax abstract on obefazimod phase 2b results selected for moderated poster presentation at UEG Week 2022Obefazimod (ABX464) interim 48-week safety and efficacy analysis from the ongoing phase 2b maintenance